Current Status and Future Prospect of Medical Radioisotopes Production in China

This study examines the current state of medical radioisotope production in China. It aims to evaluate production technologies, industrial applications, and clinical impacts of diagnostic and therapeutic radioisotopes. The work identifies barriers to progress, including limited infrastructure and a...

Full description

Saved in:
Bibliographic Details
Published inHé huàxué yŭ fàngshè huàxué Vol. 47; no. 4; pp. 444 - 455
Main Authors Kai WEN, Zhi-hao SONG, Zi-yu ZHAO, Cheng-wei MA, Fei DUAN, Hao-miao CHU, Hong-yu LI, Jin DU
Format Journal Article
LanguageChinese
Published Editorial Office of Journal of Nuclear and Radiochemistry 01.08.2025
Subjects
cyclotron
medical radioisotopes
radiopharmaceuticals
reactor
Online AccessGet full text
ISSN0253-9950
DOI10.7538/hhx.2025.47.04.0444

Cover

More Information
Summary:This study examines the current state of medical radioisotope production in China. It aims to evaluate production technologies, industrial applications, and clinical impacts of diagnostic and therapeutic radioisotopes. The work identifies barriers to progress, including limited infrastructure and a reliance on imported materials. It proposes solutions to enhance self-sufficiency and scalability. The ultimate goal is to strengthen nuclear medicine for diagnosing and treating diseases like cancer, heart conditions, and neurological disorders. A systematic literature review was performed, covering peer-reviewed articles, industry reports, and government documents from 2015 to 2025. Radioisotopes were categorized into diagnostic isotopes for single-photon emission computed tomography(SPECT), such as 99Tcm, 123I, and 201Tl; diagnostic isotopes for positron emission tomography(PET), including 68Ga, 64Cu, and 89Zr; and therapeutic isotopes, such as 131I, 177Lu, 90Y, 225Ac, and 211At. For each isotope, key parameters
ISSN:0253-9950
DOI:10.7538/hhx.2025.47.04.0444